Things to remember: Kevetrin now has proof of acti
Post# of 72439
And, though we don't yet know the final results for this phase of the Prurisol study, the data from the first trial were very encouraging even though the doses were lower than what this trial is using. It seems logical that bigger doses might have even better results for more patients.
We need to keep reminding potential investors of the huge progress IPIX has made, and how we are on the verge of more hard data for 3 of these drugs.